专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2014073845A1 A COMPOSITION FOR TREATING DIABETES OR DIABESITY COMPRISING OXYNTOMODULIN ANALOG 审中-公开
标题翻译：用于治疗包含氧自由基蛋白类似物的糖尿病或脂蛋白的组合物
公开(公告)号：WO2014073845A1
公开(公告)日：2014-05-15
申请号：PCT/KR2013/009990
申请日：2013-11-06
申请人： HANMI PHARM. CO., LTD.
发明人： KIM, Jin Sun , KIM, Dae Jin , LEE, Sang Hyun , JUNG, Sung Youb , KWON, Se Chang
IPC分类号： A61K38/26 , C07K14/605 , A61K39/395 , A61P3/10
CPC分类号： C07K14/575 , A61K38/22 , A61K47/643 , A61K47/6435 , C07K14/605 , C07K16/00 , C07K16/3046 , C07K2319/30 , C07K2319/31
摘要： The present invention relates to a composition for preventing or treating diabetes, disbesity or diabetic complications, comprising an oxyntomodulin analog as an active ingredient. The invention also relates to a method for treating diabetes, diabesity or diabetic complications, comprising administering a pharmaceutically effective amount of an oxyntomodulin analog to a subject. The oxyntomodulin analog has a high ability to activate the GLP-1 receptor and the glucagon receptor, compared to native oxyntomodulin. The oxyntomodulin analog induces the expansion of beta-cells and increases insulin secretion, thereby reducing blood glucose levels that were increased due to a high-calorie and high-fat diet. The oxyntomodulin analog induces decreases in body weight and diet intake to improve insulin sensitivity and allow blood glucose levels, which are not controlled due to insulin resistance, to be maintained at normal levels. Thus, the oxyntomodulin analog can be effectively used to prevent or treat of diabetes and related diseases.
摘要翻译：本发明涉及用于预防或治疗糖尿病，消瘦或糖尿病并发症的组合物，其包含胃泌酸调节素类似物作为活性成分。本发明还涉及一种治疗糖尿病，肥胖症或糖尿病并发症的方法，包括向受试者施用药学有效量的胃泌酸调节素类似物。与天然胃泌酸调节素相比，胃泌酸调节蛋白类似物具有高的活化GLP-1受体和胰高血糖素受体的能力。胃泌酸调节蛋白类似物诱导β-细胞的扩增并增加胰岛素分泌，从而降低由于高热量和高脂肪饮食而增加的血糖水平。胃泌酸调节蛋白类似物诱导体重和饮食摄取量的降低以改善胰岛素敏感性并且使由胰岛素抵抗引起的不受控制的血糖水平维持在正常水平。因此，胃泌酸调节蛋白类似物可以有效地用于预防或治疗糖尿病和相关疾病。

2. 发明申请

WO2015183054A1 COMPOSITION FOR TREATING DIABETES MELLITUS COMPRISING INSULIN AND A GLP-1/GLUCAGON DUAL AGONIST 审中-公开
标题翻译：用于治疗包含胰岛素和GLP-1 / GLUCAGON双因子的糖尿病的组合物
公开(公告)号：WO2015183054A1
公开(公告)日：2015-12-03
申请号：PCT/KR2015/005455
申请日：2015-06-01
申请人： HANMI PHARM. CO., LTD.
发明人： JUNG, Sung Youb , HWANG, Sang Youn , KIM, Seung Su , CHOI, In Young , KWON, Se Chang
IPC分类号： A61K38/28 , A61K38/26 , A61P3/10 , A61P3/00
CPC分类号： A61K38/28 , A61K38/26 , A61K47/50 , A61K47/60 , A61K47/68 , A61K47/6811 , A61K47/6889 , C07K16/46 , C07K19/00 , C07K2317/52 , C07K2317/53 , C07K2319/00 , C07K2319/30 , A61K2300/00
摘要： The present invention relates to a composition for preventing or treating diabetes mellitus comprising insulin and a GLP-1/glucagon dual agonist, and a method for preventing or treating diabetes mellitus. More specifically, the present composition can inhibit the weight gain and reduce the danger of hypoglycemia due to the administration of insulin, lower the administration dose and greatly improve the compliance of drugs through a combined administration of a long-acting insulin conjugate and a long-acting GLP-1/glucagon dual agonist conjugate. In addition, the long-acting insulin conjugate and the long-acting GLP-1/glucagon dual agonist conjugate according to the present invention can improve the in vivo sustainability and stability because an insulin and a GLP-1/glucagon dual agonist are linked to the immunoglobulin Fc region via a non-peptidyl linker.
摘要翻译：本发明涉及一种用于预防或治疗包含胰岛素和GLP-1 /胰高血糖素双重激动剂的糖尿病的组合物，以及预防或治疗糖尿病的方法。更具体地，本发明的组合物可以抑制体重增加并降低由于施用胰岛素导致的低血糖危险，降低给药剂量并通过联合施用长效胰岛素缀合物和长效胰岛素缀合物大大提高药物的依从性，作用GLP-1 /胰高血糖素双重激动剂缀合物。此外，根据本发明的长效胰岛素缀合物和长效GLP-1 /胰高血糖素双重激动剂缀合物可以改善体内的可持续性和稳定性，因为胰岛素和GLP-1 /胰高血糖素双重激动剂与通过非肽基连接子的免疫球蛋白Fc区。

3. 发明申请

WO2017003191A1 GLUCAGON DERIVATIVE AND A COMPOSITION COMPRISING A LONG ACTING CONJUGATE OF THE SAME 审中-公开
标题翻译： GLUCAGON衍生物和包含其长期活性成分的组合物
公开(公告)号：WO2017003191A1
公开(公告)日：2017-01-05
申请号：PCT/KR2016/006984
申请日：2016-06-29
申请人： HANMI PHARM. CO., LTD.
发明人： LEE, Jong Suk , LEE, Jong Min , PARK, Young Jin , LIM, Chang Ki , JUNG, Sung Youb , KWON, Se Chang
IPC分类号： A61K38/26 , A61K38/28
CPC分类号： C07K14/605 , A61K38/2264 , A61K38/2278 , A61K38/26 , A61K38/28 , A61K47/60 , A61K47/68 , A61K47/6811 , A61P3/00 , A61P3/04 , A61P3/08 , A61K2300/00
摘要： The present invention relates to a glucagon derivative, a long-acting conjugate of the glucagon derivative, and a use thereof.
摘要翻译：本发明涉及胰高血糖素衍生物，胰高血糖素衍生物的长效缀合物及其用途。

4. 发明申请

WO2016108617A1 GLUCAGON DERIVATIVES 审中-公开
标题翻译： GLUCAGON衍生物
公开(公告)号：WO2016108617A1
公开(公告)日：2016-07-07
申请号：PCT/KR2015/014481
申请日：2015-12-30
申请人： HANMI PHARM. CO., LTD.
发明人： JUNG, Sung Youb , PARK, Young Jin , LEE, Jong Suk , CHOI, Jae Hyuk , LIM, Chang Ki , KWON, Se Chang
IPC分类号： C07K14/605 , A61K38/26 , A61P3/04
CPC分类号： C07K14/605 , A61K38/00 , A61K38/26 , A61K45/06
摘要： The present invention relates to a novel peptide of a glucagon derivative and a composition for preventing or treating obesity comprising the peptide as an active ingredient. The glucagon derivative according to the present invention shows a more excellent activating effect with regard to both glucagon-like peptide-1 receptors and glucagon receptors compared to native glucagon, and thus can be widely used as an effective agent for treating obesity.
摘要翻译：本发明涉及一种胰高血糖素衍生物的新型肽和用于预防或治疗包含该肽作为活性成分的肥胖症的组合物。根据本发明的胰高血糖素衍生物与天然胰高血糖素相比，对胰高血糖素样肽-1受体和胰高血糖素受体两者显示出更优异的活化作用，因此可广泛用作治疗肥胖症的有效药剂。

5. 发明申请

WO2016043533A1 USE OF A LONG ACTING GLP-1/GLUCAGON RECEPTOR DUAL AGONIST FOR THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE 审中-公开
标题翻译：使用长效GLP-1 / GLUCAGON受体双因素治疗非酒精性脂肪肝疾病
公开(公告)号：WO2016043533A1
公开(公告)日：2016-03-24
申请号：PCT/KR2015/009753
申请日：2015-09-16
申请人： HANMI PHARM. CO., LTD.
发明人： HWANG, Sang Youn , KIM, Jin Young , KIM, Seung Su , CHOI, In Young , JUNG, Sung Youb , KWON, Se Chang
IPC分类号： A61K38/26 , A61K47/48 , A61P1/16
CPC分类号： C07K16/00 , A61K38/26 , A61K47/48215 , A61K47/48415 , A61K47/60 , A61K47/6811 , A61K49/0008 , C07K2317/41 , C07K2317/53
摘要： The present invention relates to a pharmaceutical composition for the prevention or treatment of non-alcoholic fatty liver disease including a long-acting GLP-1/glucagon receptor dual agonist, and a method for preventing or treatment of non-alcoholic fatty liver disease including administering the composition. The composition of the present invention either has no side effect of weight gain or reduces the side effect of weight gain, which is a side-effect of conventional therapeutic agents for non-alcoholic fatty liver disease, and reduces the amount of administrations of a long-acting GLP-1/glucagon receptor dual agonist, thus greatly improving patient's convenience. In addition, the long-acting GLP-1/glucagon receptor dual agonist of the present invention improves in vivo sustainability and stability.
摘要翻译：本发明涉及用于预防或治疗非酒精性脂肪肝疾病的药物组合物，其包括长效GLP-1 /胰高血糖素受体双重激动剂，以及用于预防或治疗非酒精性脂肪肝疾病的方法，包括给予组成。本发明的组合物不具有体重增加的副作用或减轻体重增加的副作用，这是常规治疗剂对非酒精性脂肪肝疾病的副作用，并且减少长时间的给药量 GLP-1 /胰高血糖素受体双重激动剂，从而大大提高了患者的便利性。此外，本发明的长效GLP-1 /胰高血糖素受体双重激动剂改善了体内可持续性和稳定性。

6. 发明申请

WO2014017843A1 COMPOSITION FOR TREATING HYPERLIPIDEMIA COMPRISING OXYNTOMODULIN DERIVATIVE 审中-公开
标题翻译：用于治疗包含氧自由基衍生物的高磷脂酰胆碱的组合物
公开(公告)号：WO2014017843A1
公开(公告)日：2014-01-30
申请号：PCT/KR2013/006668
申请日：2013-07-25
申请人： HANMI PHARM. CO., LTD.
发明人： JUNG, Sung Youb , KIM, Jin-Sun , JANG, Myung Hyun , LEE, Sang Hyun , CHOI, In Young , KWON, Se Chang
IPC分类号： A61K38/26 , A61K38/16 , A61P3/06 , A61P3/00
CPC分类号： A61K38/26 , A61K38/22 , A61K45/06 , A61K47/59 , A61K47/593 , A61K47/60 , A61K47/643 , A61K47/6435 , A61K47/68 , A61K47/6811 , C07K14/605 , C07K14/76 , C07K14/78
摘要： The present invention relates to a composition for preventing or treating hyperlipidemia, fatty liver disease or arteriosclerosis, comprising an oxyntomodulin derivative as an active ingredient. The oxyntomodulin derivative has a high ability to activate GLP-1 receptor and glucagon receptor compared to native oxyntomodulin and has the effects of reducing the blood total cholesterol, low-density cholesterol and triglyceride levels that were increased by high-fat diet, and increasing high-density cholesterol levels and the high-density cholesterol/low-density cholesterol ratio. Thus, the oxyntomodulin derivative can be effectively used for the treatment of hyperlipidemia and related diseases.
摘要翻译：本发明涉及用于预防或治疗高脂血症，脂肪肝疾病或动脉硬化的组合物，其包含胃泌酸调节素衍生物作为活性成分。胃泌酸调节蛋白衍生物与天然胃泌酸调节素相比具有高活化GLP-1受体和胰高血糖素受体的能力，并且具有降低高脂肪饮食增加的血液总胆固醇，低密度胆固醇和甘油三酯水平的作用，并且增加高密度胆固醇水平和高密度胆固醇/低密度胆固醇比值。因此，胃泌酸调节蛋白衍生物可以有效地用于治疗高脂血症和相关疾病。

7. 发明申请

WO2005038031A1 EXPRESSION VECTOR FOR SECRETING ANTIBODY FRAGMENT USING E. COLI SIGNAL SEQUENCE AND METHOD FOR MASS-PRODUCING ANTIBODY FRAGMENT 审中-公开
标题翻译：使用大肠杆菌信号序列分析抗体片段的表达载体和产生抗体片段的方法
公开(公告)号：WO2005038031A1
公开(公告)日：2005-04-28
申请号：PCT/KR2004/002625
申请日：2004-10-14
申请人： HANMI PHARM. CO., LTD. , JUNG, Sung Youb , KIM, Jin Sun , KWON, Se Chang , LEE, Gwan Sun
发明人： JUNG, Sung Youb , KIM, Jin Sun , KWON, Se Chang , LEE, Gwan Sun
IPC分类号： C12N15/70
CPC分类号： C12P21/02 , C07K16/00 , C07K16/241 , C07K2317/55 , C07K2319/00 , C07K2319/02 , C12N15/70
摘要： A recombinant expression vector capable of expressing and secreting an antibody fragment fused with E. coli thermostable enterotoxin signal sequence derivative or E. coli outer membrane protein A (Omp A) signal sequence in the form of a soluble heterozygote protein is used to mass-produce the antibody fragment by culturing a microorganism transformed with the expression vector in a medium and collecting the antibody fragment secreted from the transformed microorganism into the medium.
摘要翻译：能够表达和分泌与大肠杆菌热稳定性肠毒素信号序列衍生物或可溶性杂合子蛋白质形式的大肠杆菌外膜蛋白A（Omp A）信号序列融合的抗体片段的重组表达载体用于大规模生产通过在培养基中培养用表达载体转化的微生物并将从转化的微生物分泌的抗体片段收集到培养基中的抗体片段。

8. 发明申请

WO2014119956A1 RECOMBINANT YEAST TRANSFORMANT AND PROCESS FOR PREPARING IMMUNOGLOBULIN FC FRAGMENT EMPLOYING THE SAME 审中-公开
标题翻译：用于制备使用其的免疫球蛋白FC片段的重组YETER变体和方法
公开(公告)号：WO2014119956A1
公开(公告)日：2014-08-07
申请号：PCT/KR2014/000901
申请日：2014-02-03
申请人： HANMI PHARM. CO., LTD.
发明人： KIM, Jin-Sun , HUH, Yong Ho , OH, Euh Lim , KIM, Min Young , JUNG, Sung Youb , KWON, Se Chang
IPC分类号： C12N1/19 , C12N15/13 , C12N15/81
CPC分类号： C12N15/815 , C07K16/00 , C07K2317/14 , C07K2317/52 , C12N15/81
摘要： The present invention relates to a transformant prepared by introducing an expression vector comprising a polynucleotide encoding for a human immunoglobulin Fc fragment into Pichia sp. yeast, a method for producing an immunoglobulin Fc fragment comprising culturing the transformant, and recovering the immunoglobulin Fc fragment from the culture, and an immunoglobulin Fc fragment, prepared by the above method for use as a drug carrier. The transformant is suggested as a solution to the problems associated with the use of E. coli or animal cells as hosts for producing immunoglobulin Fc fragments useful as drug carriers, so that it can find various applications in the effective and economical production of drugs.
摘要翻译：本发明涉及通过将包含编码人免疫球蛋白Fc片段的多核苷酸的表达载体导入毕赤酵母（Pichia sp。）而制备的转化体。酵母，生产免疫球蛋白Fc片段的方法，包括培养转化体，从培养物中回收免疫球蛋白Fc片段，以及通过上述方法制备的免疫球蛋白Fc片段作为药物载体。建议转化体作为解决与使用大肠杆菌或动物细胞作为用于产生用作药物载体的免疫球蛋白Fc片段的宿主相关的问题的解决方案，从而可以在药物的有效和经济生产中找到各种应用。

9. 发明申请

WO2010082804A2 METHOD FOR PRODUCING PHYSIOLOGICALLY ACTIVE PROTEIN OR PEPTIDE USING IMMUNOGLOBULIN FRAGMENT 审中-公开
标题翻译：使用免疫球蛋白片段生产生理活性蛋白质或肽的方法
公开(公告)号：WO2010082804A2
公开(公告)日：2010-07-22
申请号：PCT/KR2010/000342
申请日：2010-01-19
申请人： HANMI PHARM. CO., LTD. , KIM, Jin-Sun , JUNG, Sung Youb , LEE, Jong-Soo , LEE, Byung Sun , KWON, Se Chang , LEE, Gwan Sun
发明人： KIM, Jin-Sun , JUNG, Sung Youb , LEE, Jong-Soo , LEE, Byung Sun , KWON, Se Chang , LEE, Gwan Sun
IPC分类号： C12N15/62 , C12N15/52 , C12N15/09 , C07K19/00
CPC分类号： C07K14/00 , C07K2319/30
摘要： The present invention provides a method for mass-producing a physiologically active protein or peptide using a fusion protein composed of the physiologically active protein or peptide and an immunoglobulin fragment. The present invention also provides such a fusion protein, a DNA encoding the fusion protein, an expression vector comprising the DNA, and a microorganism transformed with the expression vector.
摘要翻译：本发明提供了一种使用由生理活性蛋白或肽和免疫球蛋白片段组成的融合蛋白来批量生产生理活性蛋白或肽的方法。本发明还提供了这样的融合蛋白，编码该融合蛋白的DNA，包含该DNA的表达载体和用该表达载体转化的微生物。

10. 发明申请

WO2017052324A1 METHOD OF PRODUCING IMMUNOGLOBULIN FC REGION INCLUDING INITIAL METHIONINE RESIDUE 审中-公开
标题翻译：生产包含初始甲硫氨酸残留的免疫球蛋白FC区的方法
公开(公告)号：WO2017052324A1
公开(公告)日：2017-03-30
申请号：PCT/KR2016/010752
申请日：2016-09-26
申请人： HANMI PHARM. CO., LTD.
发明人： JEONG, Eui Joon , HEO, Yong Ho , LEE, Jong Min , PARK, Sung Hee , JUNG, Sung Youb , KWON, Se Chang
IPC分类号： C07K16/18 , C07K19/00 , A61K47/48
CPC分类号： C07K14/705 , C07K14/57563 , C07K2319/30
摘要： The present invention relates to a method of producing a monomeric or dimeric immunoglobulin Fc region including the initial methionine residue using a vector including a nucleotide sequence encoding a recombinant immunoglobulin Fc region including an immunoglobulin hinge region, and to a monomeric or dimeric immunoglobulin Fc region including the initial methionine residue prepared by the method. A recombinant immunoglobulin Fc region including an immunoglobulin hinge region of the present invention may be used to produce a recombinant immunoglobulin Fc region as inclusion bodies in E. coli, and methionine is included in the expressed recombinant immunoglobulin Fc region. The produced immunoglobulin Fc region is linked to a physiologically active polypeptide, and is thereby used for increasing serum half-life of the physiologically active polypeptide.
摘要翻译：本发明涉及使用包含编码包含免疫球蛋白铰链区的重组免疫球蛋白Fc区的核苷酸序列的载体和包含单体或二聚体免疫球蛋白Fc区的包含初始甲硫氨酸残基的单体或二聚体免疫球蛋白Fc区的方法，通过该方法制备的初始甲硫氨酸残基。包含本发明的免疫球蛋白铰链区的重组免疫球蛋白Fc区可用于在大肠杆菌中产生作为包涵体的重组免疫球蛋白Fc区，并且所述表达的重组免疫球蛋白Fc区中包含甲硫氨酸。产生的免疫球蛋白Fc区与生理活性多肽连接，从而用于增加生理活性多肽的血清半衰期。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式